Please use this identifier to cite or link to this item:
DC FieldValueLanguage
dc.contributorShih-Chieh Changen_US
dc.contributor.authorJih-Bow Hongen_US
dc.identifier.citationAtherton, M.J., Morris, J.S., McDermott, M.R., Lichty, B.D., 2016. Cancer immunology and canine malignant melanoma: A comparative review. Veterinary immunology and immunopathology 169, 15-26. Bateman, K.E., Catton, P.A., Pennock, P.W., Kruth, S.A., 1994. 0–7–21 radiation therapy for the treatment of canine oral melanoma. Journal of veterinary internal medicine 8, 267-272. Becker, M.R., Siegelin, M.D., Rompel, R., Enk, A.H., Gaiser, T., 2009. COX-2 expression in malignant melanoma: a novel prognostic marker? Melanoma research 19, 8-16. Bergin, I., Smedley, R., Esplin, D., Spangler, W., Kiupel, M., 2011. Prognostic evaluation of Ki67 threshold value in canine oral melanoma. Veterinary pathology 48, 41-53. Bocca, C., Bozzo, F., Bassignana, A., Miglietta, A., 2011. Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Molecular and cellular biochemistry 350, 59-70. Bocca, C., Bozzo, F., Cannito, S., Parola, M., Miglietta, A., 2012. Celecoxib inactivates epithelial–mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells. Molecular carcinogenesis 51, 783-795. Borzacchiello, G., Russo, V., Russo, M., 2007. Immunohistochemical Expression of Cyclooxygenase‐2 in Canine Ovarian Carcinomas. Transboundary and Emerging Diseases 54, 247-249. Bostock, C., Clark, E., Harding, N., Mounts, P., Tyler-Smith, C., Van Heyningen, V., Walker, P., 1979. The development of resistance to methotrexate in a mouse melanoma cell line. Chromosoma 74, 153-177. Bostock, D., 1979. Prognosis after surgical excision of canine melanomas. Veterinary Pathology 16, 32-40. Cangul, I., Van Garderen, E., Van Der Linde-Sipman, J., van den Ingh, T., Schalken, J., 2001. Canine balloon and signet-ring cell melanomas: a histological and immunohistochemical characterization. Journal of comparative pathology 125, 166-173. Cha, Y.I., DuBois, R.N., 2007. NSAIDs and cancer prevention: targets downstream of COX-2. Annu. Rev. Med. 58, 239-252. Choi, C., Kusewitt, D., 2003. Comparison of tyrosinase-related protein-2, S-100, and Melan A immunoreactivity in canine amelanotic melanomas. Veterinary pathology 40, 713-718. Choisunirachon, N., Jaroensong, T., Yoshida, K., Saeki, K., Mochizuki, M., Nishimura, R., Sasaki, N., Nakagawa, T., 2015. Effects of low-dose cyclophosphamide with piroxicam on tumour neovascularization in a canine oral malignant melanoma-xenografted mouse model. Vet Comp Oncol 13, 424-432. Chwirot, B.W., Kuzbicki, L., 2007. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours. Melanoma research 17, 139-145. Cochran, A.J., Wen, D.R., Herschman, H.R., Gaynor, R.B., 1982. Detection of S‐100 protein as an aid to the identification of melanocytic tumors. International journal of cancer 30, 295-297. Dhawan, D., Craig, B.A., Cheng, L., Snyder, P.W., Mohammed, S.I., Stewart, J.C., Zheng, R., Loman, R.A., Foster, R.S., Knapp, D.W., 2010. Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Molecular cancer therapeutics 9, 1371-1377. Dore, M., Lanthier, I., Sirois, J., 2003. Cyclooxygenase-2 expression in canine mammary tumors. Veterinary pathology 40, 207-212. Freeman, K.P., Hahn, K.A., Harris, F.D., King, G.K., 2003. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum‐based chemotherapy (1987–1997). Journal of veterinary internal medicine 17, 96-101. Giudice, C., Ceciliani, F., Rondena, M., Stefanello, D., Grieco, V., 2010. Immunohistochemical investigation of PNL2 reactivity of canine melanocytic neoplasms and comparison with Melan A. Journal of veterinary diagnostic investigation 22, 389-394. González-García, R., Naval-Gías, L., Martos, P., Nam-Cha, S., Rodríguez-Campo, F., Muñoz-Guerra, M., Sastre-Perez, J., 2005. Melanoma of the oral mucosa. Clinical cases and review of the literature. Medicina oral, patologia oral y cirugia bucal 10, 264-271. Gregorio, H., Raposo, T.P., Queiroga, F.L., Prada, J., Pires, I., 2016. Investigating associations of cyclooxygenase-2 expression with angiogenesis, proliferation, macrophage and T-lymphocyte infiltration in canine melanocytic tumours. Melanoma Res 26, 338-347. Grimes, J.A., Matz, B.M., Christopherson, P.W., Koehler, J.W., Cappelle, K.K., Hlusko, K.C., Smith, A., 2017. Agreement Between Cytology and Histopathology for Regional Lymph Node Metastasis in Dogs With Melanocytic Neoplasms. Vet Pathol 54, 579-587. Gustafsson, A., Hansson, E., Kressner, U., Nordgren, S., Andersson, M., Wang, W., Lonnroth, C., Lundholm, K., 2007. EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer 121, 232-240. Hahn, K., DeNicola, D., Richardson, R., Hahn, E., 1994. Canine oral malignant melanoma: prognostic utility of an alternative staging system. Journal of small animal practice 35, 251-256. Harvey, H., MacEwen, E., Braun, D., Patnaik, A., Withrow, S., Jongeward, S., 1981. Prognostic criteria for dogs with oral melanoma. Journal of the American Veterinary Medical Association 178, 580. Herschman, H.R., 2004. PET reporter genes for noninvasive imaging of gene therapy, cell tracking and transgenic analysis. Critical reviews in oncology/hematology 51, 191-204. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., 2016. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35-44. Impellizeri, J.A., Esplin, D.G., 2008. Expression of cyclooxygenase-2 in canine nasal carcinomas. Veterinary journal (London, England : 1997) 176, 408-410. Iussich, S., Maniscalco, L., Di Sciuva, A., Iotti, B., Morello, E., Martano, M., Gattino, F., Buracco, P., De Maria, R., 2017. PDGFRs expression in dogs affected by malignant oral melanomas: correlation with prognosis. Vet Comp Oncol 15, 462-469. Khan, K.N., Stanfield, K.M., Trajkovic, D., Knapp, D.W., 2001. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol 38, 116-119. Kim, S.-H., Song, S.-H., Kim, S.-G., Chun, K.-S., Lim, S.-Y., Na, H.-K., Kim, J.W., Surh, Y.-J., Bang, Y.-J., Song, Y.-S., 2004. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-κB as a possible target. Journal of cancer research and clinical oncology 130, 551-560. Koenig, A., Wojcieszyn, J., Weeks, B., Modiano, J., 2001. Expression of S100a, vimentin, NSE, and Melan A/MART-1 in seven canine melanoma cell lines and twenty-nine retrospective cases of canine melanoma. Veterinary pathology 38, 427-435. Kurzman, I.D., MacEwen, E.G., Rosenthal, R.C., Fox, L.E., Keller, E.T., Helfand, S.C., Vail, D.M., Dubielzig, R.R., Madewell, B.R., Rodriguez, C.O., 1995. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clinical cancer research 1, 1595-1601. L'Eplattenier, H.F., Lai, C.L., van den Ham, R., Mol, J., van Sluijs, F., Teske, E., 2007. Regulation of COX-2 expression in canine prostate carcinoma: increased COX-2 expression is not related to inflammation. J Vet Intern Med 21, 776-782. Laprie, C., Abadie, J., Amardeilh, M.F., Net, J.L., Lagadic, M., Delverdier, M., 2001. MIB‐1 immunoreactivity correlates with biologic behaviour in canine cutaneous melanoma. Veterinary dermatology 12, 139-147. Lascelles, B., 2003. Relief of chronic cancer pain. BSAVA manual of oncology. 2nd ed. Cheltenham, UK: BSAVA Publications, 137-151. Lavalle, G., Bertagnolli, A., Tavares, W., Cassali, G., 2009. Cox-2 expression in canine mammary carcinomas: correlation with angiogenesis and overall survival. Veterinary Pathology 46, 1275-1280. Lee, J.Y., Tanabe, S., Shimohira, H., Kobayashi, Y., Oomachi, T., Azuma, S., Ogihara, K., Inokuma, H., 2007. Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma. Res Vet Sci 83, 210-216. Liptak, J.M., Forrest, L.J., 2007. Soft tissue sarcomas. Small animal clinical oncology 4, 425-454. Liptak, J.M., Lascelles, X., Duncan, B., Kudnig, S.T., Séguin, B., 2012. Oral tumors. Veterinary surgical oncology, 119-177. Liu, C.H., Lin, C.H., Tsai, M.J., Chen, Y.H., Yang, S.F., Tsai, K.B., 2018. Melanin Bleaching With Warm Hydrogen Peroxide and Integrated Immunohistochemical Analysis: An Automated Platform. International journal of surgical pathology, 1066896918756998. Liu, H., Huang, P., Xu, X., Liu, J., Guo, C., 2009. Anticancer effect of celecoxib via COX-2 dependent and independent mechanisms in human gastric cancers cells. Digestive diseases and sciences 54, 1418-1424. MacEwen, E.G., Patnaik, A., Harvey, H., Hayes, A., Matus, R., 1986. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer investigation 4, 397-402. Mainetti, L.E., Rozados, V.R., Rossa, A., Bonfil, R.D., Scharovsky, O.G., 2011. Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas. J Cancer Res Clin Oncol 137, 151-163. Marconi, D., Resende, B., Rauber, E.F., Soares, P.C., Junior, J.F., Carvalho, A.L., Kupelian, P., Chen, A., 2015. Superficial X-ray Therapy for Non-Melanoma Skin Cancer of the Head and Neck: Comparative Analysis of H-Zone Versus Non-H-Zone Lesions. International Journal of Radiation Oncology• Biology• Physics 93, E315. Martínez, C., Peñafiel-Verdú, C., Vilafranca, M., Ramírez, G., Méndez-Gallego, M., Buendía, A., Sánchez, J., 2011. Cyclooxygenase-2 expression is related with localization, proliferation, and overall survival in canine melanocytic neoplasms. Veterinary pathology 48, 1204-1211. Masferrer, J.L., Zweifel, B.S., Seibert, K., Needleman, P., 1990. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. The Journal of clinical investigation 86, 1375-1379. Matsuyama, A., Schott, C.R., Wood, G.A., Richardson, D., Woods, J.P., Mutsaers, A.J., 2018. Evaluation of metronomic cyclophosphamide chemotherapy as maintenance treatment for dogs with appendicular osteosarcoma following limb amputation and carboplatin chemotherapy. J Am Vet Med Assoc 252, 1377-1383. Millanta, F., Andreani, G., Rocchigiani, G., Lorenzi, D., Poli, A., 2016. Correlation Between Cyclo-oxygenase-2 and Vascular Endothelial Growth Factor Expression in Canine and Feline Squamous Cell Carcinomas. J Comp Pathol 154, 297-303. Millanta, F., Fratini, F., Corazza, M., Castagnaro, M., Zappulli, V., Poli, A., 2002. Proliferation activity in oral and cutaneous canine melanocytic tumours: correlation with histological parameters, location, and clinical behaviour. Research in veterinary science 73, 45-51. Mohammed, S., Khan, K., Sellers, R., Hayek, M., DeNicola, D., Wu, L., Bonney, P., Knapp, D., 2004. Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. Prostaglandins, leukotrienes and essential fatty acids 70, 479-483. Morton, D.L., Wen, D.-R., Wong, J.H., Economou, J.S., Cagle, L.A., Storm, F.K., Foshag, L.J., Cochran, A.J., 1992. Technical details of intraoperative lymphatic mapping for early stage melanoma. Archives of surgery 127, 392-399. Mukaratirwa, S., Chikafa, L., Dliwayo, R., Moyo, N., 2006. Mast cells and angiogenesis in canine melanomas: malignancy and clinicopathological factors. Veterinary dermatology 17, 141-146. Murphy, S.A., 2005. An experimental design for the development of adaptive treatment strategies. Statistics in medicine 24, 1455-1481. Needleman, P., Truk, J., Jakschik, B.A., Morrison, A.R., Lefkowith, J.B., 1986. Arachidonic acid metabolism. Annual review of biochemistry 55, 69-102. Ogino, S., Kirkner, G.J., Nosho, K., Irahara, N., Kure, S., Shima, K., Hazra, A., Chan, A.T., Dehari, R., Giovannucci, E.L., Fuchs, C.S., 2008. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 14, 8221-8227. Oliveira, V.M., Piato, S., Silva, M.A., 2006. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium. Breast cancer research and treatment 95, 235-241. Orchard, G.E., Calonje, E., 1998. The effect of melanin bleaching on immunohistochemical staining in heavily pigmented melanocytic neoplasms. The American Journal of dermatopathology 20, 357-361. Ottnod, J., Smedley, R., Walshaw, R., Hauptman, J., Kiupel, M., Obradovich, J., 2013. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Veterinary and comparative oncology 11, 219-229. Paglia, D., Dubielzig, R.R., Kado-Fong, H.K., Maggs, D.J., 2009. Expression of cyclooxygenase-2 in canine uveal melanocytic neoplasms. American journal of veterinary research 70, 1284-1290. Pires, I., Garcia, A., Prada, J., Queiroga, F., 2010. COX-1 and COX-2 expression in canine cutaneous, oral and ocular melanocytic tumours. Journal of comparative pathology 143, 142-149. Proulx, D.R., Ruslander, D.M., Dodge, R.K., Hauck, M.L., Williams, L.E., Horn, B., Sylvester Price, G., Thrall, D.E., 2003. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Veterinary Radiology & Ultrasound 44, 352-359. Przezdziecki, R., Czopowicz, M., Sapierzynski, R., 2015. Accuracy of routine cytology and immunocytochemistry in preoperative diagnosis of oral amelanotic melanomas in dogs. Veterinary clinical pathology 44, 597-604. Queiroga, F.L., Alves, A., Pires, I., Lopes, C., 2007. Expression of Cox-1 and Cox-2 in canine mammary tumours. J Comp Pathol 136, 177-185. Queiroga, F.L., Pires, I., Lobo, L., Lopes, C.S., 2010. The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours. Research in veterinary science 88, 441-445. Queiroga, F.L., Pires, I., Parente, M., Gregório, H., Lopes, C.S., 2011. COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer. The Veterinary Journal 189, 77-82. Ramos-Vara, J., Beissenherz, M., Miller, M., Johnson, G., Pace, L., Fard, A., Kottler, S., 2000. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Veterinary Pathology 37, 597-608. Salmenkivi, K., Haglund, C., Ristimaki, A., Arola, J., Heikkila, P., 2001. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. The Journal of clinical endocrinology and metabolism 86, 5615-5619. Schultheiss, P.C., 2006. Histologic features and clinical outcomes of melanomas of lip, haired skin, and nail bed locations of dogs. Journal of veterinary diagnostic investigation 18, 422-425. Schwarz, P., Withrow, S., Curtis, C., Powers, B., Straw, R., 1991. Partial maxillary resection as a treatment for oral cancer in 61 dogs. The Journal of the American Animal Hospital Association (USA). Seo, K.W., Coh, Y.R., Rebhun, R.B., Ahn, J.O., Han, S.M., Lee, H.W., Youn, H.Y., 2014. Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines. Res Vet Sci 96, 482-486. Shen, H., Wu, W., 2015. Study of melanin bleaching after immunohistochemistry of melanin-containing tissues. Applied immunohistochemistry & molecular morphology : AIMM 23, 303-307. Smedley, R., Spangler, W., Esplin, D., Kitchell, B., Bergman, P., Ho, H.-Y., Bergin, I., Kiupel, M., 2011. Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation. Veterinary Pathology 48, 54-72. Smith, S., Goldschmidt, M., McManus, P., 2002. A comparative review of melanocytic neoplasms. Veterinary Pathology 39, 651-678. Soumaoro, L.T., Uetake, H., Higuchi, T., Takagi, Y., Enomoto, M., Sugihara, K., 2004. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 10, 8465-8471. Spangler, W., Kass, P., 2006. The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. Veterinary pathology 43, 136-149. Sweet, M., Kirkham, N., Bendall, M., Currey, L., Bythell, J., Heupel, M., 2012. Evidence of melanoma in wild marine fish populations. PloS one 7, e41989. Tanaka, N., Mimura, M., Ogi, K., Amagasa, T., 2004. Primary malignant melanoma of the oral cavity: assessment of outcome from the clinical records of 35 patients. International journal of oral and maxillofacial surgery 33, 761-765. Theon, A., Madewell, B., Moore, A., Stephens, C., Krag, D., 1991. Localized thermo-cisplatin therapy: a pilot study in spontaneous canine and feline tumours. International journal of hyperthermia 7, 881-892. Tuohy, J.L., Selmic, L.E., Worley, D.R., Ehrhart, N.P., Withrow, S.J., 2014. Outcome following curative-intent surgery for oral melanoma in dogs: 70 cases (1998–2011). Journal of the American Veterinary Medical Association 245, 1266-1273. Wallace, J.M., Smith, C., Bretherton, C.S., 1992. Singular value decomposition of wintertime sea surface temperature and 500-mb height anomalies. Journal of climate 5, 561-576. Wang, D., DuBois, R.N., 2006. Prostaglandins and cancer. Gut 55, 115-122.zh_TW
dc.description.abstract惡性黑色素瘤(MM)具有局部侵犯特性並伴隨高遠端轉移率和較短的存活時間,管理此疾病上仍充滿挑戰。近期有文獻指出,使用與腫瘤進展相關的環氧合酶-2(COX-2)作為治療標的,例如以非類固醇類消炎藥(NSAIDs)來治療惡性黑色素瘤。先前的研究顯示其中一種NSAIDs即piroxicam,對於特定腫瘤如移形上皮細胞癌具有抗腫瘤活性。本研究的目的為探討(1)惡性黑色素瘤在不同解剖位置(口腔內但非舌頭、舌頭、腳趾)之COX-2表現,與(2)在接受piroxicam治療的患犬中COX-2表現與總存活時間(OST)的關聯,並進一步比較其與臨床和病理型態學因子之相關性。OST定義為發現腫瘤至病犬死亡之間期。此篇回溯型研究共收集84隻經組織病理學確診為惡性黑素瘤的患犬。COX-2的表現以免疫組織化學法來測定並評估免疫反應分級、強度和反應程度分數。單變因分析顯示COX-2表現與OST沒有顯著相關性,但腫瘤位置則顯著影響OST(P<0.05)。在48隻接受piroxicam治療的患犬分組中,COX-2的反應程度分數和強度僅於單變因分析結果發現與OST顯著相關(P<0.05)。多變因分析結果顯示piroxicam治療 分組中有接受手術切除、原發於腳趾位置、發現腫瘤時間至確診時間較久的患犬之OST較長(P <0.05)。此篇研究發現COX-2表現量與犬惡性黑色素瘤的腫瘤發生位置無關,但在piroxicam治療的患犬若COX-2表現較高則有較好的預後。因此,COX-2表現量可能作為惡性黑色素瘤患犬在接受piroxicam輔助治療的指標。zh_TW
dc.description.abstractMalignant melanomas (MM) are locally aggressive and associated with high metastatic potential and shorter survival time, which remained a challenge to management. Cyclooxygenase-2 (COX-2), which is thought to involve in the tumor progression, has recently been suggested as a therapeutic target such as nonsteroidal anti-inflammatory drugs (NSAIDs) in MM. Previous reports have demonstrated that piroxicam, one of NSAIDs, has an antitumor activity on certain tumors such as transitional cell carcinoma. The aims of this study were to investigate (1) the COX-2 expression of MM at different locations (non-lingual oral, tongue and digital location), and (2) the correlation between COX-2 expression and the overall survival time (OST) of dogs that had piroxicam, and further comparing with the related clinico-morphological factors. The OST is defined from tumor first noted to death. This retrospective study enrolled 84 dogs that were diagnosed as malignant melanoma histopathologically. The COX-2 expression was determined immunohistochemically for the evaluation of immunoreactivity grade, intensity, and reactivity score. The univariate analysis revealed that COX-2 expression had no significant impact on OST. However, tumor location had significantly associated with OST (P < 0.05). Of 48 dogs in the piroxicam-treated group, COX-2 score and intensity were significant related to OST (P < 0.05) in univariate analysis but not in multivariate analysis. Results of multivariate analysis revealed that surgical removal, digital location, and the long time between observation to diagnosis were positively associated with OST (P < 0.05) in the piroxicam-treated group. This study demonstrated that COX-2 expression level was not associated with tumor locations, and piroxicam-treated group with high COX-2 expression had better outcomes. In conclusion, the COX-2 expression level may be used as an indicator for piroxicam adjuvant therapy in dogs with MM.en_US
dc.description.tableofcontents致謝 i 中文摘要 ii Abstract iii List of Tables vi List of Figures vii List of Abbreviations viii Chapter 1 Introduction 1 Chapter 2 Material and Methods 8 2.1 Animals 8 2.2 Medical records and sampling 9 2.3 Treatment protocol 10 2.4 Immunohistochemistry 12 2.5 Statistical analysis 17 Chapter 3 Results 18 3.1 Clinic-histological records 18 3.2 COX-2 immunoreactivity 21 3.2.1 COX-2 immunolabeling analysis 21 3.2.2 Pathological features associated with COX-2 expression in the Pearson Chi-square test. 21 3.3 Survival analysis 23 3.3.1 Analysis according to clinicpathologic features of overall survival time (OST) in MM group. 23 3.3.2 Analysis according to clinicpathologic features of overall survival time (OST) in piroxicam-treated group of dogs with MM 26 Chapter 4 Discussion 31 References 36zh_TW
dc.subjectCanine malignant melanomaen_US
dc.subjectCyclooxygenase-2 expressionen_US
dc.subjecttumor locationen_US
dc.titleCOX-2 expression at various anatomical sites and related clinical outcome in dogs with malignant melanomaen_US
dc.typethesis and dissertationen_US
item.openairetypethesis and dissertation-
item.fulltextwith fulltext-
Appears in Collections:獸醫學系所
Files in This Item:
File SizeFormat Existing users please Login
nchu-107-7104038109-1.pdf1.25 MBAdobe PDFThis file is only available in the university internal network    Request a copy
Show simple item record

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.